Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie

Zotatifin [2098191-53-6]

Drucken

Katalog-Nummer NB-64-08240-1mg

Size : 1mg

Marke : Neo Biotech

Weitere Informationen anfordern

Remove All

Zotatifin

(Synonyms: eFT226, eFT 226) Copy Product Info

Hot

Synonyms: eFT226, eFT 226

Catalog No. T17296 Copy Product Info

Purity: 99.61%

Hot

Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and anticancer activities, blocking tumor growth driven by receptor tyrosine kinases and inhibiting Sox4 translation, inducing apoptosis.

Cas No. 2098191-53-6

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.61%

Appearance:Solid

Color:White

Product Introduction

Bioactivity

Description	Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and anticancer activities, blocking tumor growth driven by receptor tyrosine kinases and inhibiting Sox4 translation, inducing apoptosis.
Targets & IC50	eIF4A:2 nM
In vitro	Methods: Zotatifin (0.0001 μM-1 μM, 72 hours) was used to treat MDA-MB-231 cells, and the antiproliferative activity was determined. Results: Zotatifin showed potent antiproliferative activity in MDA-MB-231 tumor cells, with a GI50 value of less than 15 nM. TMD8 and Pfeiffer DLBCL tumor cells were treated with Zotatifin (30 μM-100 μM, 3 or 24 hours), and the changes in protein levels were detected by WB. Results: Zotatifin reduced the expression of MYC, CCND3, BCL2, and MCL1 proteins in a time- and dose-dependent manner.[1]
In vivo	Methods: Zotatifin (1 mg/kg, intravenous injection, 14-22 days) was used to treat mice bearing TMD8 xenografts, HBL1 xenografts, Pfeiffer xenografts, SU-DHL-6 xenografts, SU-DHL-10 xenografts, and Ramos xenografts, and the tumor inhibition rate was observed. Results: The tumor growth percentages of various tumor xenograft model mice after Zotatifin treatment were 97%, 87%, 70%, 83%, 37%, and 75%, respectively. Methods: Zotatifin (0.001 mg/kg-1 mg/kg, intravenous injection; 15 days) was used to treat mice bearing B-cell lymphoma xenograft models, and the tumor growth in vivo was observed. Results: Zotatifin inhibited the growth of B-cell lymphoma xenografts and was well tolerated in B-cell lymphoma xenograft models in vivo.[2]
Synonyms	eFT226, eFT 226

Chemical Properties

Molecular Weight	487.55
Formula	C₂₈H₂₉N₃O₅
Cas No.	2098191-53-6
Smiles	O[C@]12[C@]([C@@H]([C@@H](CN(C)C)[C@H]1O)C3=CC=CC=C3)(OC=4C2=C(OC)N=C(OC)C4)C5=CC=C(C#N)C=C5
Relative Density.	1.36 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 150 mg/mL (307.66 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.26 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.0511 mL	10.2554 mL	20.5107 mL	102.5536 mL
5 mM	0.4102 mL	2.0511 mL	4.1021 mL	20.5107 mL
10 mM	0.2051 mL	1.0255 mL	2.0511 mL	10.2554 mL
20 mM	0.1026 mL	0.5128 mL	1.0255 mL	5.1277 mL
50 mM	0.0410 mL	0.2051 mL	0.4102 mL	2.0511 mL
100 mM	0.0205 mL	0.1026 mL	0.2051 mL	1.0255 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

ZotatifineIF4AeFT-226

Related Tags: Zotatifin chemical structure | Zotatifin in vivo | Zotatifin in vitro | Zotatifin formula | Zotatifin molecular weight